These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1801 related articles for article (PubMed ID: 27338353)

  • 21. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
    Zuo L; Motherwell MS
    Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective Effect of Oral Hesperetin Against Unilateral Striatal 6-Hydroxydopamine Damage in the Rat.
    Kiasalari Z; Khalili M; Baluchnejadmojarad T; Roghani M
    Neurochem Res; 2016 May; 41(5):1065-72. PubMed ID: 26700436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
    Cacabelos R
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease.
    Badillo-Ramírez I; Saniger JM; Rivas-Arancibia S
    Neurochem Int; 2019 Oct; 129():104514. PubMed ID: 31369776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of endoplasmic reticulum stress in Parkinson's disease.
    Tsujii S; Ishisaka M; Hara H
    Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minocycline: neuroprotective mechanisms in Parkinson's disease.
    Thomas M; Le WD
    Curr Pharm Des; 2004; 10(6):679-86. PubMed ID: 14965330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valeric Acid Protects Dopaminergic Neurons by Suppressing Oxidative Stress, Neuroinflammation and Modulating Autophagy Pathways.
    Jayaraj RL; Beiram R; Azimullah S; Mf NM; Ojha SK; Adem A; Jalal FY
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.
    Pinto M; Nissanka N; Peralta S; Brambilla R; Diaz F; Moraes CT
    Mol Neurodegener; 2016 Apr; 11():25. PubMed ID: 27038906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baicalin Represses C/EBP
    Lei K; Shen Y; He Y; Zhang L; Zhang J; Tong W; Xu Y; Jin L
    Oxid Med Cell Longev; 2020; 2020():8951907. PubMed ID: 32566108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Chinese herbal formula Liuwei dihuang protects dopaminergic neurons against Parkinson's toxin through enhancing antioxidative defense and preventing apoptotic death.
    Tseng YT; Chang FR; Lo YC
    Phytomedicine; 2014 Apr; 21(5):724-33. PubMed ID: 24411708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
    Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
    Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Targets for Parkinson's Disease: Addressing Different Therapeutic Paradigms and Conundrums.
    Rane P; Sarmah D; Bhute S; Kaur H; Goswami A; Kalia K; Borah A; Dave KR; Sharma N; Bhattacharya P
    ACS Chem Neurosci; 2019 Jan; 10(1):44-57. PubMed ID: 29957921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.
    Schepici G; Silvestro S; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the norepinephrinergic system in Parkinson's disease and related disorders: The locus coeruleus story.
    Vermeiren Y; De Deyn PP
    Neurochem Int; 2017 Jan; 102():22-32. PubMed ID: 27899296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dietary Natural Flavonoids: Intervention for MAO-B Against Parkinson's Disease.
    Singh A; Sinha S; Singh NK
    Chem Biol Drug Des; 2024 Sep; 104(3):e14619. PubMed ID: 39223743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson's disease: a short story of 200 years.
    Cuenca L; Gil-Martinez AL; Cano-Fernandez L; Sanchez-Rodrigo C; Estrada C; Fernandez-Villalba E; Herrero MT
    Histol Histopathol; 2019 Jun; 34(6):573-591. PubMed ID: 30540129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk.
    Paudel YN; Angelopoulou E; Piperi C; Shaikh MF; Othman I
    Pharmacol Res; 2020 Feb; 152():104593. PubMed ID: 31843673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 91.